Picture of Kiora Pharmaceuticals logo

KPRX — Kiora Pharmaceuticals News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMicro CapNeutral

Kiora Pharmaceuticals Inc expected to post a loss of 60 cents a share - Earnings Preview

Kiora Pharmaceuticals Inc KPRX.OQ KPRX.O is expected to  show a rise in quarterly revenue when it reports  results on August 7 (estimated) for the period ending June 30 2025

The Encinitas California-based  company is expected to report a 3,650.0% increase in revenue to $750 thousand from $20 thousand a year ago, according to the mean estimate from 2 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Kiora Pharmaceuticals Inc is for a loss of 60 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Kiora Pharmaceuticals Inc is $11.00, about 76.9% above its last closing price of $2.54

This summary was machine generated August 5 at 14:37 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Recent news on Kiora Pharmaceuticals

See all news